)
Schrödinger (SDGR) investor relations material
Schrödinger UBS Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Platform and strategy
Molecular-discovery platform serves life sciences and a growing materials-science market; software licensing is the primary monetization model, alongside early-stage therapeutics, collaborations and NewCos.
Product development extends beyond small-molecule discovery into formulations and biologics, with continued platform advances and AI capabilities.
Physics-based simulation generates data to supplement limited experimental data for AI models; internal GPU capacity supports 30,000–40,000 accurate binding-affinity calculations daily for internal programs.
Accuracy, 30 years of development, more than $1 billion invested in the platform, and feedback from a 200-person therapeutics team were cited as competitive advantages.
Bunsen and AI adoption
Bunsen, an AI agent for running discovery workflows, had internal working versions more than a year ago; scientists validated it by Q4 last year, and it is currently in beta.
Bunsen aims to expand calculation throughput and make workflows more accessible; it can guide users, flag potential errors and support less experienced scientists, while still requiring expert oversight.
A typical pharma workflow could screen far more candidate molecules before selecting a smaller set for synthesis, potentially improving success probability and speeding discovery decisions.
Bunsen sessions can scale a computational chemist’s work across multiple concurrent tasks; results and experimental data can feed into LiveDesign to inform molecule selection.
Materials-science adoption is an opportunity: Bunsen could help individual users follow best practices and shorten service-led onboarding into software sales.
Software model and growth
Licensing is based on software instances and calculation throughput, not user seats; greater Bunsen usage is expected to drive demand for more licenses.
ACV is expected to increase 12%–17% this year from $198 million; growth spans top-20 pharma, other life-science and materials customers, new products and new customers.
Large pharma represents roughly half of commercial business; better biotech funding conditions also supported growth.
Bunsen has contributed to license growth while in beta; customers are evaluating it and completing security reviews, with further license-package uptake expected as adoption develops.
Predictive Tox had profiled 80 off-targets; further profiling is needed to increase customer utility, while Bunsen and other products continue to evolve.
- Q3 revenue and ACV grew, prompting higher FY26 guidance amid hosted adoption and a $37.7M net loss.SDGR
Q3 2026 - AI-driven platform innovation and hosted solutions fuel growth, with profitability targeted by 2028.SDGR
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 saw 27% ACV growth, $58.9M revenue, and a return to profitability.SDGR
Q2 2026 - Shifting to R&D and partnerships, with robust revenue growth and key clinical data ahead.SDGR
Jefferies London Healthcare Conference 2025 - All proposals passed and strategic focus remains on AI-driven molecular discovery innovation.SDGR
AGM 2026 - 23% revenue growth to $255.9M, strong cash, and hosted transition target positive EBITDA by 2028.SDGR
Q4 2025 - Major Novartis deal and advancing clinical pipeline position the company for strong growth.SDGR
Jefferies London Healthcare Conference 2024 - Q2 revenue up 35% to $47.3M; net loss $54M; Gates grant and pipeline drive growth.SDGR
Q2 2024 - Novartis deal, strong software growth, and $398.4M cash offset lower drug discovery revenue.SDGR
Q3 2024
)
)
)
)
)
)
)
)